Press release from Companies
Published: 2025-11-04 08:30:00
Inhalation Sciences announced today that the company has engaged the international transaction advisor PharmaVentures LTD to evaluate existing contacts and initiate new ones with potential acquirers of the company's operations. The purpose of the assignment is to assess the possibility of realizing the highest possible shareholder value from Inhalation Sciences' world-leading patented technologies and extensive knowledge in inhalation research. The company expects to be able to conclude the process within 9-12 months.
For many years, Inhalation Sciences has sold services and instruments related to the company's patented technology platform, PreciseInhale®, to customers in the pharmaceutical and environmental sectors. In 2025, the results of a study initiated and funded by the FDA were published, externally validating PreciseInhale's® unique capabilities.
"We have many customers who are at the forefront of development within their segments, and PreciseInhale® is used, among other things, to accelerate and reduce risks in the development of new drugs. With the positive results from the FDA study, we have noticed increased interest in our systems and services", says Manoush Masarrat, CEO of ISAB.
In connection with the Q4 2024 report, Inhalation Sciences informed that the board is evaluating several strategic opportunities for the company.
"In light of the technical and commercial progress we have made over the years, the Board has seen concrete interest from parties in exploring more extensive strategic opportunities, which may include the acquisition of the company or its operations. Until now, we have managed such discussions internally on an ongoing basis, but we have now chosen to seek external help to both broaden our contacts and evaluate more systematically the opportunities that the company itself has met", says Manoush Masarrat, CEO of ISAB.
PharmaVentures Ltd., an international transaction advisor who has advised on over 1,000 transaction related assignments in pharmaceuticals and medtech over the past 30 years.
"We have evaluated both Nordic and international transaction advisors and chose PharmaVentures because we believe they are best able to represent us in discussions with the types of actors who have shown interest in Inhalation Sciences and our business. Our expectation is to be able to conclude the process with PharmaVentures within 9 - 12 months", says Manoush Masarrat, CEO of ISAB.
This disclosure contains information that Inhalation Sciences is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on November 4, 2025 at 08:30.
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.
